Existing evidence on the use of gabapentinoids in chronic low back pain (CLBP) is limited, and demonstrates significant risk of adverse effects with no benefits on pain relief, according to a meta-analysis published in PLOS Medicine by Harsha Shanthanna from McMaster University, Canada, and colleagues.
Gabapentinoids, including pregabalin and gabapentin, are increasingly used for non-specific CLBP. In the new study, researchers analysed findings from eight randomised controlled trials that investigated the use of gabapentinoids in adult CLBP patients.
In three studies comparing gabapentin to placebo, gabapentin showed no significant improvement of pain; and in the three studies comparing pregabalin to other analgesics, pregabalin actually fared worse in pain relief. There were no deaths or hospitalisations reported in any included studies of the drugs, but commonly reported adverse events included dizziness, fatigue, confusion, and visual disturbances. Functional and emotional outcomes among patients taking gabapentinoids for CLBP showed no significant improvements.
“Despite their widespread use, our systematic review with meta-analysis found that there are very few randomised controlled trials that have attempted to assess the benefit of using gabapentin or pregabalin in patients of chronic low back pain,” the authors say. “The existing evidence does not support the use of gabapentinoids for predominant chronic low back pain, and calls for larger, high quality trials to more definitively inform this issue.”
Source: Science Daily
Reference: Harsha Shanthanna, Ian Gilron, Manikandan Rajarathinam, Rizq AlAmri, Sriganesh Kamath, Lehana Thabane, Philip J. Devereaux, Mohit Bhandari. Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. PLOS Medicine, 2017; 14 (8): e1002369 DOI: 10.1371/journal.pmed.1002369